Illinois Tech Journal
SEE OTHER BRANDS

Your science and technology news reporter from Illinois

Illinois Tech Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Illinois Tech Journal.

Press releases published on August 14, 2025

Zarla Named #1 AI Website Builder by The SMB Guide

Zarla Named #1 AI Website Builder by The SMB Guide

Recognized for speed, no‑code setup, and SEO‑first design, Zarla helps brand‑new small service businesses launch professional websites in minutes. CHICAGO, IL, UNITED STATES, August 14, 2025 /⁨EINPresswire.com⁩/ -- Zarla, an AI Website Builder for small …

Royal Cyber Unveils Generative AI Solution to Accelerate COBOL-to-Java Mainframe Modernization with AWS Transform

Royal Cyber Unveils Generative AI Solution to Accelerate COBOL-to-Java Mainframe Modernization with AWS Transform

New Generative AI-powered solution modernizes COBOL apps to Java in months, cutting timelines by 50% and reducing manual effort by 90%. NAPERVILLE, IL, UNITED STATES, August 14, 2025 /⁨EINPresswire.com⁩/ -- Royal Cyber Inc., a global leader in IT …

Marble Box Scales to 800+ Full-Time Insurance Specialists Across Policy, Claims, and Accounting

Marble Box Scales to 800+ Full-Time Insurance Specialists Across Policy, Claims, and Accounting

CHICAGO, IL, UNITED STATES, August 14, 2025 /⁨EINPresswire.com⁩/ -- Marble Box, a leading provider of back-office staffing solutions for insurance agencies and carriers, has surpassed 800 full-time insurance professionals on its team — a milestone that …

Dscout Launches Partner Panels with Respondent to Expand Access to Global Research Participants

Dscout Launches Partner Panels with Respondent to Expand Access to Global Research Participants

Quantity meets quality: Dscout now connects researchers to over 3 million participants, with the depth and influence you expect from Dscout’s platform. CHICAGO, IL, UNITED STATES, August 14, 2025 /⁨EINPresswire.com⁩/ -- Dscout, the flexible experience …

Alliance Creative Group (ACGX) Releases 2025 Q2 Quarterly  Financial and Disclosure Report

Alliance Creative Group (ACGX) Releases 2025 Q2 Quarterly Financial and Disclosure Report

Strategic Shift Toward Phased Rollouts, Digital Asset Expansion, AI Automation, and Network Monetization Alliance Creative Group, Inc. (OTCMKTS:ACGX) CHICAGO, IL, UNITED STATES, August 14, 2025 /⁨EINPresswire.com⁩/ -- Alliance Creative Group (ACGX) …

AppTech Payments Corp. Highlights Q2 2025 Financial and Strategic Developments

AppTech Payments Corp. Highlights Q2 2025 Financial and Strategic Developments

CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- AppTech Payments Corp. (“AppTech” or the “Company”) (NASDAQ: APCX), a fintech company innovating payment solutions for businesses, today announced financial results for the second quarter ended June 30, …

VERSES Announces Filing of Quarterly Report on Form 10-Q

VERSES Announces Filing of Quarterly Report on Form 10-Q

VANCOUVER, British Columbia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) ("VERSES" or the "Company"), a cognitive computing company pioneering next-generation agentic software systems today announced that it has filed its …

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH

Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today …

Digi Power X Reports Solid Mid-Year Financial Position, Removal of ‘Going Concern’ Risk and Positive Adjusted EBITDA in Q2 2025

Digi Power X Reports Solid Mid-Year Financial Position, Removal of ‘Going Concern’ Risk and Positive Adjusted EBITDA in Q2 2025

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“ …

YXT.com to Announce Financial Results for the First Six Months of 2025 on August 20, 2025

YXT.com to Announce Financial Results for the First Six Months of 2025 on August 20, 2025

SUZHOU, China, Aug. 14, 2025 (GLOBE NEWSWIRE) -- YXT.com Group Holding Limited (NASDAQ: YXT) (“YXT.com” or the “Company”), a provider of AI-enabled enterprise productivity solutions in China, today announced that it plans to report its financial results …

INVO Fertility Announces Second Quarter 2025 Financial Results

INVO Fertility Announces Second Quarter 2025 Financial Results

SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and …

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company’s listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “ …

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis …

BioSyent Schedules Q2 and H1 2025 Earnings Release for August 21, 2025

BioSyent Schedules Q2 and H1 2025 Earnings Release for August 21, 2025

MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and six months ended June 30, 2025 on Thursday, August 21, 2025 after market …

CELOXFI Implements Military-Grade Security Protocols, Achieves 100% User Asset Insurance Coverage

CELOXFI Implements Military-Grade Security Protocols, Achieves 100% User Asset Insurance Coverage

GOLDEN, CO , Aug. 14, 2025 (GLOBE NEWSWIRE) -- Celoxfi, the AI-powered crypto asset exchange, today announced a landmark upgrade to its security infrastructure, setting a new industry benchmark for user protection. The platform has secured 100% insurance …

Veea Inc. Announces Closing of $9.2 Million Public Offering

Veea Inc. Announces Closing of $9.2 Million Public Offering

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Veea Inc. (NASDAQ: VEEA) (“Veea” or the “Company”), a leader in intelligent edge infrastructure, announced the closing of its public offering of an aggregate of 9,189,096 shares of common stock and warrants to …

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, …

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights

PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-year Invivyd’s target of near-term profitability (1H 2025) was not met but remains possible with the upcoming respiratory virus season …

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Alignment follows Type C meeting for VYD2311 as previously disclosed BLA pathway for VYD2311 to be supported by a single, Phase 2/3 randomized, double-blind, placebo-controlled trial with a primary endpoint of reduction in symptomatic COVID-19, resembling …

MDB Capital Holdings to Host Second Quarter 2025 Update Conference Call on Wednesday August 27, 2025, at 4:30 p.m. Eastern Time

MDB Capital Holdings to Host Second Quarter 2025 Update Conference Call on Wednesday August 27, 2025, at 4:30 p.m. Eastern Time

Addison, TX, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading disruptive technology companies, plans to host a Zoom webinar on Wednesday August 27, 2025 at …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions